



14th ANNUAL

T-CELL LYMPHOMA FORUM

A comprehensive program designed to update attendees on all the latest findings about T-cell Lymphoma, including global epidemiology, prognostic markers and tools, pathobiology, clinical management, global implications, and latest clinical trial findings.

JUNE 23–25, 2022



SPONSORSHIP AND EXHIBIT PROSPECTUS

www.tcellforum.com

Hosted by

Medscape **LIVE!**



Global Academy for
Medical Education

PROGRAM INFORMATION

OVERVIEW

The 14th Annual T-cell Lymphoma Forum is a two-and-a-half-day meeting focusing on the latest information on novel agents and treatment approaches. The Forum, co-chaired by Francine M. Foss, MD, Won Seog Kim, MD, PhD, and Owen A. O'Connor, MD, PhD, provides a composite platform to facilitate progress in TCL research by addressing the hurdles that have confronted oncologists and ultimately paves the way for improved outcomes for patients.

TARGET AUDIENCE

This meeting is intended for hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphomas.

CO-CHAIR/PLANNING COMMITTEE

**Francine M. Foss, MD**

Professor of Medicine
Section of Medical Oncology
Yale University School of Medicine
Smilow Cancer Center
New Haven, Connecticut, United States

**Won Seog Kim, MD, PhD**

Professor
Division of Hematology/Oncology
Samsung Medical Center
Sungkyunkwan University
School of Medicine
Seoul, Republic of Korea

**Owen A. O'Connor, MD, PhD**

American Cancer Society
Research Professor
Director, Program for T-cell Lymphoma
Department of Medicine
Division of Hematology and Oncology
University of Virginia Cancer Center
Charlottesville, Virginia, United States

AGENDA

THURSDAY, JUNE 23, 2022

10:00 AM – 11:00 AM PST

TBD Bonus Presentation

12:30 PM – 1:30 PM PST

TBD Bonus Presentation

1:30 PM – 2:00 PM PST

Visit Exhibit and Poster Halls

Welcome and Keynote

2:00 PM – 2:05 PM PST

Welcome and Introduction of Keynote Speaker

2:05 PM – 2:50 PM PST

Keynote Address: The Gradual Evolution of Treatment in PTCL: Is it Time to Embrace a New Punctuated Equilibrium?

Owen A. O'Connor, MD, PhD

SESSION I

Epidemiology and Classification

2:50 PM – 3:05 PM PST

A Focus on Rare PTCL Subtypes: Clinicopathologic Correlations

Pier Paolo Piccaluga

3:05 PM – 3:20 PM PST

Deciphering the Heterogeneity of PTCL NOS: Making the Case Why this Matters to the Treating Physician

Laurence Leval

3:20 PM – 3:35 PM PST

What will PTCL Classification Look Like in the Next WHO Report?

Elaine Jaffee

3:35 PM – 3:50 PM PST

Agent Orange and the Link with CTCL and PTCL in Veterans: What does the data say

Helen Ma

3:50 PM – 4:05 PM PST

An Update from the 9/11 Health Monitoring Project:

Michael Crane or Phillip Landrigan

4:05 PM – 5:00 PM PST

Live Q&A/Panel Discussion

Welcome Dinner

5:00 PM – 6:00 PM PST

TBD Bonus Presentation

6:00 PM – 6:15 PM PST

Break/Cocktails

6:15 PM – 8:15 PM PST

Welcome Dinner/Recognition of Research Award Winners
(in memory of Dr. Waldmann and Dr. Bertino)

FRIDAY, JUNE 24, 2022

SESSION II

Molecular Biology and Pathogenesis

7:00 AM – 8:00 AM PST

TBD Bonus Presentation

8:00 AM – 8:25 AM PST

Break/Visit Exhibit and Poster Halls

8:25 AM – 8:30 AM PST

Day 2 Welcome

8:30 AM – 8:45 AM PST

Molecular Classification of the PTCL: What's New and How Will it Influence Practice?
Iqubaal

8:45 AM – 9:45 AM PST

Understanding the Opportunity to Quantitate Minimal Residual Disease in PTCL

• **Lecture #1: How does one measure MRD in patients with hematologic malignancies, and why?**

Sherif Ibrahim

• **Lecture #2: The Status of MRD analyses in TCLF**

John Chan or Matthew Ahearne

9:45 AM – 10:00 AM PST

T-cell Receptor Driven Lymphomagenesis: From Mouse to Human, Does it Translate?

Irving L. Weissman

10:00 AM – 10:15 AM PST

Most Recent Advances in the Pathogenesis of T-cell lymphoma

Kojo S. J. Elenitoba-Johnson

10:15 AM – 10:45 AM PST

Live Q&A/Discussion

10:45 AM – 11:05 AM PST

Break/Visit Exhibit and Poster Halls

SESSION III

T-Cell Lymphoma Subtypes

11:05 AM – 11:20 AM PST

Liquid Biologics

WS Kim

11:20 AM – 11:35 AM PST

Susceptibility to ENKTL?

Xinzin Bei

11:35 AM – 11:50 AM PST

Prognostic Value of Single-nucleotide Polymorphisms for Extranodal Natural Killer/T-cell Lymphoma: The Identification of Risk Factors in the Molecular Era

Cai QQ

AGENDA

11:50 AM – 12:05 PM PST

How Animal Models of ATLL Have Changed Our Thinking Around Disease Biology

Bazabarachi

12:05 PM – 12:20 PM PST

Chronological Genome and Single-Cell Transcriptome Integration Characterizes the Evolutionary Process of Adult T-cell Leukemia-Lymphoma.

Yamagishi M

12:20 PM – 12:35 PM PST

EBV+cytotoxic nodal T-cell lymphoma

Shigeo Nakamura (Nagoya JP)

12:35 PM – 12:55 PM PST

Live Q&A/Discussion

1:00 PM – 2:00 PM PST

TBD Bonus Presentation

SESSION IV

Treatment – Chemotherapy vs Non-Chemotherapy Options in the Front-Line

2:00 PM – 2:15 PM PST

CHOP-Romidepsin in the Front-line

Michael Crump

2:15 PM – 2:30 PM PST

Still CHOP? The Merits or NOT of CHOP Addition Studies

Kim SJ

2:30 PM – 2:45 PM PST

What's the Argument for non-Chemotherapy Options in the Front-line

Enrica Marchi

2:45 PM – 3:00 PM PST

Debate

I Transplant All Eligible Patients in the Front-line

D'Amore

I Never Recommend ASCT in the Front-line

Zinzani

3:00 PM – 3:15 PM PST

What Subtypes Would I Perform an Allogeneic Stem Cell Transplant on in the Front-line

Corradini

3:15 PM – 3:30 PM PST

Live Q&A/Discussion

Moderated by Owen A. O'Connor, MD, PhD

3:30 PM – 3:50 PM PST

Break/Visit Exhibit and Poster Halls

SESSION V

CTCL

3:50 PM – 4:05 PM PST

Quantitating Clinical Benefits of New Treatments in CTCL: Is It Time to Move On From SWAT

Miles Prince, MD

4:05 PM – 4:20 PM PST

Will Adoptive Cellular Therapies Ever Have a Routine Role in CTCL?

Julia Scarisbrick, MD

4:20 PM – 4:35 PM PST

Is There an Optimal Treatment for Patients With Transformed Mycosis Fungoides?

Foss, Francine

4:35 PM – 4:50 PM PST

Pathways and Drugs- Screening Novel Agents And Combinations in CTCL

Michael Girardi (Yale)

4:50 PM – 5:05 PM PST

Live Q&A/Discussion

Poster Presentations

5:05 PM – 6:05 PM PST

Poster Presentations

6:05 PM – 7:05 PM PST

Poster Walk Reception

7:05 PM – 8:05 PM PST

TBD Bonus Presentation

SATURDAY, JUNE 25, 2022

7:00 PM – 8:00 PM PST

TBD Bonus Presentation

8:00 PM – 8:05 PM PST

Day 4 Opening Remarks

WS Kim, MD, PhD

SESSION VI

Novel Therapies on the PTCL Horizon

8:05 AM – 8:20 AM PST

Adoptive Cellular treatment of PTCL: Just How Much Longer Should This Take?

Ann Bevin

Marco Ruella Penn

8:20 AM – 8:35 AM PST

Allogeneic Gamma elta T-cells for PTCL

Speaker: TBD

Company: TBD

AGENDA

8:35 AM – 8:50 AM PST***Targeting T-cells with Bispecific Antibodies: Are there any Prospects for Application in PTCL***

Lawrence Lum UVA

8:50 AM – 9:05 AM PST***The Newest Small Molecules Under Study in PTCL***

Weiyun Ai

9:05 AM – 9:20 AM PST***Monoclonal Antibodies*****9:20 AM – 9:35 AM PST*****The Landscape of New Drugs in Extranodal NK/T-cell Lymphoma***

Liang Wanga

9:35 AM – 9:50 AM PST***Case Report - Transformation of BCEL to a TCEL Lymphoma***

Mubarak Al Mansour

9:50 AM – 10:05 AM PST**Live Q&A/Discussion****SESSION VII*****Industry Innovations*****10:05 AM – 10:20 AM PST*****CART Company from Korea***

Await WSK recommendation

10:20 AM – 10:35 AM PST***New Strategies for Targeting CD30***

Andre Shustov

10:35 AM – 10:50 AM PST***How Nanoparticle Chemistry is Changing our Approach to Therapeutics: The mRNA COVID19 Paradigm***

Mark Kester – Keystone/UVA

10:50 AM – 11:05 AM PST***RAPT Therapeutics-small Molecule Target for CCR4***

Bill Ho

11:05 AM – 11:20 AM PST***Targeting Cell Surface Heat Shock Protein 70 for T-cell Lymphomas***

Bob Orlowski

11:20 AM – 11:35 AM PST***PI3K in PTCL***

Korean Pharmacy – WSK to recommend faculty

SESSION VIII***Wrap-up Highlights*****11:35 AM – 12:35 PM PST*****Roundtable Discussion***

Topic 1: TBD

Topic 2: TBD

Topic 3: TBD

12:35 PM – 12:40 PM PST***Day 4 Closing Remarks***

All Co-Chairs

1:00 PM – 2:00 PM PST**TBD Bonus Presentation**

Agenda subject to change | Please refer to the virtual platform for the most up-to-date information.

SPONSORSHIP OPPORTUNITIES

DIAMOND LEVEL | \$95,000

- 1–45 minute time slot for a non-CME industry expert presentation. (Live in-person, and live streamed)
- Premium exhibit space: 2 Spaces
- Badges for up to 8 exhibitors
- One insert in conference bag
- Two-page, 4-color ad in exhibitor/sponsor guide
- Sponsorship signage throughout exhibit/registration areas and on conference website
- Post conference eblast to attendees (client to provide fully approved HTML)
- 1 Door drop
- Key card sponsor

GOLD LEVEL | \$50,000

- Premium exhibit space: 2 spaces
- Badges for up to 6 exhibitors
- One insert in conference bag
- Two-page 4-color ad in exhibitor/sponsor guide
- Sponsorship signage throughout exhibit/registration areas and on conference website
- Post conference eblast to attendees (client to provide fully approved HTML)

SILVER LEVEL | \$42,500

- Exhibit space
- Badges for up to 4 exhibitors
- One insert in conference bag
- One-page b/w ad in exhibitor/sponsor guide
- Sponsorship signage throughout exhibit/registration areas and on conference website
- Post conference eblast to attendees (client to provide fully approved HTML)

BRONZE LEVEL | \$25,000

- Exhibit space
- Badges for 3 exhibitors
- One conference bag insert
- One-page b/w ad in exhibitor/sponsor guide
- Sponsorship signage throughout exhibit/registration areas and on conference website

EXHIBIT | \$3,750

- Tabletop display
- 2 Exhibitor badges

EXPERT SESSIONS (Non-CME)

- Proposal/application must be submitted to Global Academy by May 27, 2022 (Must be an exhibitor or sponsor)

LIMITED TIME-SLOTS

FIRST COME, FIRST SERVED.

- Morning, mid-day and end-of-day slots currently available

SLOT FEE MUST BE PAID IN FULL PRIOR TO EVENT (45 Min)

- \$45,000 morning
- \$50,000 mid-day
- \$40,000 end-of-day

SLOT FEE INCLUDES

- In addition to the live, in-person audience, your session will also be live-streamed to our virtual audience.
- Standard AV
- Session room
- Announcement on conference website
- Distribution of supplied traffic drivers
- Posting of supplied signage

ANY SUPPLEMENTS/WEBCASTS, ETC. MUST BE PUBLISHED WITH ANY OF THE FOLLOWING:

- MDEdge Hematology and Oncology

Bonus Presentation Time Slots (Non-CME or CME)

- Thursday, June 23 | 10:00 AM – 11:00 AM
- Thursday, June 23 | 12:30 PM – 1:30 PM
- Friday, June 24 | 7:00 AM – 8:00 AM
- Friday, June 24 | 12:30 PM – 1:30 PM
- Saturday, June 25 | 7:00 AM – 8:00 AM
- Saturday, June 25 | 1:00 PM – 2:00 PM

All bonus presentation slots listed in Pacific Time

Questions about sponsor/exhibitor opportunities?

Contact / Devin Gregorie

P 516.381.8613 | F 631.350.7251

EMAIL dgregorie@medscapelive.com

SPONSORSHIP APPLICATION

Company Name _____ Contact Name _____

Title _____ E-mail _____

Phone _____ Fax _____

Street _____ City _____

State/Province _____ ZIP/Postal Code _____

Signature _____ Date _____

SPONSORSHIP LEVEL

☐ **Diamond:** \$95,000 ☐ **Gold:** \$50,000 ☐ **Silver:** \$42,500 ☐ **Bronze:** \$25,000 ☐ **Exhibit:** \$3,750

BILLING ADDRESS

☐ Check if billing information is the same as above

Company Name _____ Contact Name _____

Title _____ E-mail _____

Phone _____ Fax _____

Street _____ City _____

State/Province _____ ZIP/Postal Code _____

Signature _____ Date _____

IMPORTANT INSTRUCTIONS Please return form to Devin Gregorie via email dgregorie@medscapelive.com.
QUESTIONS? Devin Gregorie, 516.381.8613